GAS5 and neoplasm: Moreover, multivariate Cox models adjusted for tumour stage, grade, EORTC-risk group, patients’ gender and age demonstrated the independent clinical predictive value of GAS5 loss for NMIBC relapse (HR: 2.680; 95% CI: 1.248–5.753; p = 0.011) and progression (HR: 6.362; 95% CI: 1.144–35.39; p = 0.035).